D Ross Camidge

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
    A J Atherly
    Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado, Aurora, CO, USA
    Br J Cancer 106:1100-6. 2012
  2. doi request reprint Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    D Ross Camidge
    University of Colorado Cancer Center, Mail Stop F704, 1665 Aurora Court, ACP Room 2256, Aurora, CO 80045, USA
    Cancer Chemother Pharmacol 71:307-19. 2013
  3. pmc Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    D Ross Camidge
    University of Colorado Denver, Aurora, CO, USA
    Lancet Oncol 13:1011-9. 2012
  4. pmc Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer
    D Ross Camidge
    University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4486-94. 2012
  5. pmc Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    D Ross Camidge
    Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P O Box 6510, Mail Stop F 706, Aurora, CO 80045 0508, USA
    J Thorac Oncol 6:774-80. 2011
  6. pmc Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
    D Ross Camidge
    Division of Medical Oncology and Department of Pathology, University of Colorado Denver, 1665 North Ursula Street, Aurora, CO 80045 0508, USA
    Clin Cancer Res 16:5581-90. 2010
  7. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
  8. doi request reprint Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib
    Gregory N Gan
    Department of Radiation Oncology, University of Colorado, Aurora, Colorado Electronic address
    Int J Radiat Oncol Biol Phys 88:892-8. 2014
  9. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
  10. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012

Detail Information

Publications34

  1. pmc The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
    A J Atherly
    Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado, Aurora, CO, USA
    Br J Cancer 106:1100-6. 2012
    ..We examined the impact of different predictive biomarker screening techniques and population enrichment criteria on the cost-effectiveness of targeted drugs in lung cancer, using ALK and crizotinib to build the initial model...
  2. doi request reprint Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    D Ross Camidge
    University of Colorado Cancer Center, Mail Stop F704, 1665 Aurora Court, ACP Room 2256, Aurora, CO 80045, USA
    Cancer Chemother Pharmacol 71:307-19. 2013
    ..To determine the maximum tolerated dose (MTD), safety and tolerability of sunitinib plus pemetrexed and cisplatin for advanced solid malignancies...
  3. pmc Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    D Ross Camidge
    University of Colorado Denver, Aurora, CO, USA
    Lancet Oncol 13:1011-9. 2012
    ..We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study...
  4. pmc Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer
    D Ross Camidge
    University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4486-94. 2012
    ..Increased copy numbers of fused and rearranged signals also occur. Here, correlations are explored between the percentage of ALK+ cells and signal copy number and their association with response to ALK inhibition...
  5. pmc Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    D Ross Camidge
    Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P O Box 6510, Mail Stop F 706, Aurora, CO 80045 0508, USA
    J Thorac Oncol 6:774-80. 2011
    ..To explore whether the progression-free survival (PFS) with pemetrexed differs between anaplastic lymphoma kinase (ALK)-positive and other major molecular subtypes of non-small cell lung cancer...
  6. pmc Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
    D Ross Camidge
    Division of Medical Oncology and Department of Pathology, University of Colorado Denver, 1665 North Ursula Street, Aurora, CO 80045 0508, USA
    Clin Cancer Res 16:5581-90. 2010
    ..We explored the heterogeneity basis, the requirements for accurately determining ALK FISH positivity, and the effect of enriching the tested population using clinical and molecular factors...
  7. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
    ....
  8. doi request reprint Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib
    Gregory N Gan
    Department of Radiation Oncology, University of Colorado, Aurora, Colorado Electronic address
    Int J Radiat Oncol Biol Phys 88:892-8. 2014
    ..To analyze the durability and toxicity of radiotherapeutic local ablative therapy (LAT) applied to extra-central nervous system (eCNS) disease progression in anaplastic lymphoma kinase-positive non-small cell lung cancer (NSCLC) patients...
  9. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  10. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  11. ncbi request reprint Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer
    Eamon M Berge
    Division of Medical Oncology, University of Colorado, Aurora, CO Electronic address
    Clin Lung Cancer 14:636-43. 2013
    ..Retrospective analyses suggest enhanced sensitivity to pemetrexed in crizotinib naive ALK+ NSCLC. Cross-resistance between crizotinib and pemetrexed has not been previously investigated...
  12. ncbi request reprint New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Robert C Doebele
    University of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA
    Lung Cancer 69:1-12. 2010
    ....
  13. doi request reprint Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Cancer 118:5302-9. 2012
    ..The objective of this study was to document the differences in testosterone (T) levels between crizotinib-treated and noncrizotinib-treated patients with metastatic nonsmall cell lung cancer (NSCLC)...
  14. ncbi request reprint Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer
    Neha P Amin
    Departments of Radiation Oncology, University of Colorado, School of Medicine, Aurora, Colorado, USA
    J Thorac Oncol 6:1553-62. 2011
    ..This study compared radiation therapy (RT) plans based on pre- and postchemotherapy computed tomography (CT) scans of patients with SCLC to estimate the reduced risk of radiation pneumonitis (RP) after receiving chemotherapy...
  15. pmc A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 29:3567-73. 2011
    ....
  16. pmc Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Robert C Doebele
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA
    Clin Cancer Res 18:1472-82. 2012
    ..This study aimed to define molecular mechanisms of resistance to crizotinib in patients with ALK(+) non-small cell lung cancer (NSCLC)...
  17. pmc Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:1467-77. 2013
    ..In the current review, the authors summarize the diagnostic tests available, or likely to become available, that could be used to identify patients with ALK-positive NSCLC, highlighting the pros and cons of each...
  18. pmc Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
    Kurtis D Davies
    Division of Medical Oncology, University of Colorado, MS 8117, 12801 E 17th Ave, Aurora, CO 80045, USA
    Clin Cancer Res 18:4570-9. 2012
    ..In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets...
  19. ncbi request reprint Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC
    Scott A Kono
    Thoracic Oncology Program, University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA
    Oncology (Williston Park) 23:424-9. 2009
    ....
  20. doi request reprint A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
    Qing Zhou
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Invest New Drugs 29:340-6. 2011
    ..This first-in-human phase I study evaluated the tolerability, pharmacokinetics and preliminary evidence of activity of ENMD-1198 in advanced cancer patients...
  21. ncbi request reprint Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
    Stephen Leong
    Division of Medical Oncology, University of Colorado Health Sciences Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 27:4413-21. 2009
    ....
  22. doi request reprint A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies
    D Ross Camidge
    Department of Medical Oncology, University of Colorado, Denver, Colorado, USA
    Clin Cancer Res 16:1256-63. 2010
    ..This first-in-human study assessed the safety, tolerability, pharmacokinetics, and any early evidence of efficacy of PRO95780 in patients with advanced malignancies...
  23. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  24. pmc A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    Andrew Weickhardt
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 7:419-26. 2012
    ....
  25. doi request reprint Treating ALK-positive lung cancer--early successes and future challenges
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA ross camidge ucdenver edu
    Nat Rev Clin Oncol 9:268-77. 2012
    ....
  26. ncbi request reprint From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer
    Glen J Weiss
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncology (Williston Park) 20:1515-24; discussion 1524-5, 1530, 1535. 2006
    ..Together, these developments have moved us away from the nihilism of 20 years ago into an era of unprecedented optimism in taking on the many remaining challenges of managing NSCLC in the 21st century...
  27. ncbi request reprint Targeted manipulation of apoptosis in cancer treatment
    Justin A Call
    Developmental Therapeutics and Gastrointestinal Malignancies Programs, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA
    Lancet Oncol 9:1002-11. 2008
    ..This Review summarises the rationale for direct manipulation of various elements of apoptosis and describes agents that are currently under investigation in early-phase clinical trials in many different cancer types...
  28. ncbi request reprint Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli
    Lian Zhang
    Department of Pharmacology, University of Colorado, School of Medicine, Aurora, CO, USA
    Clin Cancer Res 16:4478-89. 2010
    ....
  29. ncbi request reprint The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer
    D Ross Camidge
    Developmental Therapeutics and Thoracic Malignancies Programs, University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA
    Clin Lung Cancer 8:413-9. 2007
    ..Trials of DR4/5-directed therapies in combination with standard first-line chemotherapy for non-small-cell lung cancer are under way...
  30. ncbi request reprint The intersection between cannabis and cancer in the United States
    Daniel W Bowles
    Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Crit Rev Oncol Hematol 83:1-10. 2012
    ....
  31. doi request reprint Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making
    Todd M Erickson
    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Thorac Oncol 3:1353-5. 2008
    ....
  32. ncbi request reprint Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    D Ross Camidge
    Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Expert Opin Biol Ther 8:1167-76. 2008
    ..Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2)...
  33. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
    ..In this report, the second in a two-part series, we review clinical trials of brain metastases in relation to measures of clinical benefit and provide a framework for the design and conduct of future trials. ..
  34. ncbi request reprint The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers
    D Ross Camidge
    Developmental Therapeutics Program, University of Colorado Cancer Center, Denver Thoracic Oncology Program, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    Clin Lung Cancer 10:262-72. 2009
    ..Explorations of aspects of ligands, binding proteins, receptors, and receptor substrates are all ongoing to identify potential biomarkers predictive of benefit from IGF axis intervention...